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Abstract
The large surface area for gas exchange makes the respiratory system particularly 
susceptible to oxidative stress-mediated injury. Both endogenous and exogenous 
pro-oxidants (e.g. cigarette smoke) trigger activation of leukocytes and host 
defenses. These mechanisms interact in a “multilevel cycle” responsible for the 
control of the oxidant/antioxidant homeostasis. Several studies have demonstrated 
the presence of increased oxidative stress and decreased antioxidants (e.g. 
reduced glutathione [GSH]) in subjects with chronic obstructive pulmonary 
disease (COPD), but the contribution of oxidative stress to the pathophysiology of 
COPD is generally only minimally discussed. The aim of this review was to provide 
a comprehensive overview of the role of oxidative stress in the pathogenesis of 
respiratory diseases, particularly COPD, and to examine the available clinical and 
experimental evidence on the use of the antioxidant N-acetylcysteine (NAC), a 
precursor of GSH, as an adjunct to standard therapy for the treatment of COPD. The 
proposed concept of “multilevel cycle” helps understand the relationship between 
respiratory diseases and oxidative stress, thus clarifying the rationale for using 
NAC in COPD. Until recently, antioxidant drugs such as NAC have been regarded 
only as mucolytic agents. Nevertheless, several clinical trials indicate that NAC 
may reduce the rate of COPD exacerbations and improve small airways function. 
The most plausible explanation for the benefi cial effects observed in patients 
with COPD treated with NAC lies in the mucolytic and antioxidant effects of this 
drug. Modulation of bronchial infl ammation by NAC may further account for these 
favorable clinical results.
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Introduction
Th e primary role of the respiratory system is to provide an adequate sup-
ply of oxygen (O2) to the tissues, in order to ensure normal oxygenation and 
organ functions. Th e large surface area for gas exchange makes the respira-
tory system particularly susceptible to oxidative stress-mediated injury: both 
the high environmental O2 concentration in the lung and exogenous pollut-
ants inhaled through the breath may play a role in the production of pro-
oxidant reactive oxygen species (ROS) and reactive nitrogen species (RNS). 
Endogenous and exogenous pro-oxidants trigger cellular activation, with the 
release of proinfl ammatory mediators and proteases, and host defenses such 
as antioxidant enzymatic and non-enzymatic systems. All these mechanisms 
interact in a “multilevel cycle” responsible for the control of the oxidant/anti-
oxidant homeostasis. Oxidative stress resulting from an oxidant/antioxidant 
imbalance in favor of oxidants causes biological modifi cations that are impli-
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may be caused and/or aggravated by the exposure to air 
pollution and cigarette smoke. 
In fact, inhaled oxidants initiate a number of patho-
logic processes, including infl ammation of the airways, 
that may contribute to the pathogenesis and/or exacerba-
tion of respiratory diseases (1). Recent evidence indicates 
that exposure to environmental pollution, even at low 
levels, can increase the risk of emergency admissions for 
acute respiratory diseases and exacerbation of obstruc-
tive lung diseases in the general population (2), likely due 
to an increase in lung infl ammation (3). Cigarette smoke 
contains a very high number of chemical compounds, 
and both the tar and gas phases contain numerous free 
radicals and other oxidants (4) that may induce an oxi-
dant/antioxidant imbalance within the lung (5).
Chronic obstructive pulmonary disease (COPD) is a 
pathological lung condition directly related to cigarette 
smoke (6). Th ere is now a large body of evidence that an 
increase in oxidative stress plays an important role in the 
pathogenesis of COPD (7). Markers of oxidative stress 
have been demonstrated in the airways, breath conden-
sate, sputum, blood, and urine of smokers and patients 
with COPD (4, 6). Th ere is also evidence that endogenous 
antioxidants such as reduced glutathione (GSH) and lung 
GSH biosynthesizing enzymes are signifi cantly decreased 
in these patients (8). Furthermore, oxidative stress has 
been reported to increase further, and GSH levels to be 
depleted, during severe COPD exacerbations (9). Inhaled 
bronchodilators and inhaled corticosteroids are the main-
stay of treatment for COPD (6, 10). However, given their 
key role in the pathogenesis of COPD, oxidative stress 
and infl ammation could represent promising therapeutic 
targets for the treatment of this disease (11, 12). 
N-acetylcysteine (NAC) is a precursor of L-cysteine 
and GSH that has been used for decades as a mucolytic 
agent in the treatment of diff erent respiratory diseases. 
Being a precursor of GSH synthesis, NAC may provide 
additional benefi ts in conditions such as COPD, where 
the endogenous GSH pool is depleted. Several studies 
have investigated the role of NAC in the treatment of 
COPD. Th e aim of this review was to provide a compre-
hensive overview of the role of ROS and oxidative stress 
in the pathogenesis of respiratory diseases, particularly 
COPD, and to review the available clinical and experi-
mental evidence on the use of NAC as an adjunct to 
standard treatment for COPD. 
Lung and oxidative stress: 
Pathophysiology
Oxidative stress occurs in response to the production 
of cellular ROS and RNS during endogenous metabolic 
reactions. Inhaled oxidants in the ambient air, includ-
ing ozone, nitrogen dioxide, diesel exhaust and cigarette 
smoke, are also well-established causes of oxidative stress. 
Under normal conditions, the production of endogenous 
ROS is tightly regulated, and endogenous antioxidants 
protect tissues against the exposure to free radicals (13). 
Although low-to-moderate concentrations of ROS 
and RNS are necessary for physiological functions such 
as defense against infectious agents and cellular sig-
naling pathways (13), uncontrolled activation of ROS 
production leading to an imbalance between oxidants 
and antioxidants such as GSH can have detrimental 
consequences (Figure 1). Th e most common ROS, i.e. 
the superoxide anion (O
−
2•) and the hydroxyl radical 
Figure 1. Etiology and pathogenic role of oxidative stress in COPD. An excess in pro-oxidants (e.g. cigarette smoke) may overwhelm the antioxidant defense system of the body, 
causing an oxidant/antioxidant imbalance and therefore oxidative stress. Oxidative stress is involved many of the pathogenic processes underlying COPD, such as direct tissue 
damage, inactivation of antiproteases, mucus hypersecretion, vascular barrier dysfunction leading to edema of the bronchial wall, bronchoconstriction (both via direct action 
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(•OH), are directly associated with oxidative modifi ca-
tions of biochemical systems such as proteins, lipids and 
carbohydrates. Oxidative stress is involved many of the 
pathogenic processes underlying COPD, such as direct 
tissue damage, inactivation of antiproteases, mucus 
hypersecretion, vascular barrier dysfunction leading 
to edema of the bronchial wall, bronchoconstriction 
and enhanced lung infl ammation through activation 
of redox-sensitive transcription factors in leukocytes 
(7, 14, 15) (Figure 1).
The multilevel cycle
Figure 2 illustrates the multilevel interpretation of the 
relationship between oxidative stress and lung dam-
age. Th e interaction of exogenous pro-oxidants such as 
cigarette smoke or air pollutants with the bronchial epi-
thelium and the alveolar-capillary membrane represents 
the fi rst step of the cycle. In addition to exogenous pro-
oxidants, respiratory tissues are also exposed to endog-
enous ROS. Th erefore, both exogenous and endogenous 
stimuli may lead to an increase in ROS and RNS, causing 
lipid peroxidation and oxidative damage to proteins and 
DNA and sustaining oxidative stress (5). 
In Figure 2 this cycle is identifi ed by continuous black 
arrows. Th e second level of the process is represented by 
cellular activation, both directly by endogenous oxidants 
and indirectly via production of molecular mediators 
such as tumor necrosis factor α (TNFα) by the bronchial 
epithelium. Finally, the third level is represented by the 
host defenses against oxidative stress. Th ese are very 
important, since the physiological defense system acts 
as the arbitrator between healthy and pathological con-
ditions via diff erent endogenous pathways. 
First level: outside and inside
Cigarette smoke contains large amounts of free radicals 
in both the gas and the tar phases, and is considered as 
an important risk factor for the development of various 
types of lung diseases and cancers (16). Th e gas phase 
free radicals of tobacco smoke include both inorganic 
and organic substances such as ROS, epoxides, perox-
ides, nitric oxide (NO•), nitrogen dioxide, peroxynitrite 
(ONOO
−
), peroxynitrates and many other molecules 
(17, 18). Twenty years ago Pryor and Stone reported 
that gas phase cigarette smoke contains approximately 
1015 organic radicals per puff , which are primarily of 
the alkyl, alkoxy, and peroxyl type (19). 
NO• is present in cigarette smoke in concentrations of 
500–1000 ppm, i.e. one of the major exogenous sources 
of NO• to which smokers are exposed. NO• reacts swiftly 
with the superoxide anion (O
−
2•) to form peroxynitrite 
(ONOO 
−
) and with organic peroxyl radicals to give alkyl 
peroxynitrites (ROONO) (20). In addition to cigarette 
smoke, air pollutants may also be considered as impor-
tant inductors of lung oxidative stress. Indeed, lung 
infl ammation, as particularly demonstrated in COPD, is 
Figure 2. The concept of “multilevel cycle”. The interaction of exogenous pro-oxidants such as cigarette smoke or air pollutants with the bronchial epithelium and the 
alveolar-capillary membrane represents the fi rst level, “outside and inside” (continuous black arrows). In the second level, “interaction between cellular and molecular 
mediators”, (broken arrows) cellular activation due to both exogenous and endogenous ROS and RNS triggers a vicious oxidative cycle sustained by the release of 
infl ammatory mediators and proteases activation. The second level of the process is represented by cellular activation, both directly by endogenous oxidants and indirectly 
via production of molecular mediators such as tumor necrosis factor α (TNFα) by the bronchial epithelium. Activated leukocytes release proinfl ammatory cytokines, 
chemokines and proteases that perpetrate oxidative stress. The third level, “host defense and exogenous rescue”, (dotted arrows) is represented by the host defenses 
against oxidative stress, such as GSH. O2
−•, superoxide anion; •OH, hydroxyl radical; TNFα, tumor necrosis factor alpha; IL, Interleukin; RNS, reactive nitrogen species; ROS, 
















































Copyright © 2014 Informa Healthcare USA, Inc
4 Santus et al.
related to lipid cell membrane peroxidation (21, 22), and 
it is likely that sulphur dioxide (SO2), particulate matter 
of less than 10 microns in diameter (PM10), cold air and 
a variety of hydrated metal ions contribute to airways 
cytotoxicity, infl ammation and mucociliary clearance 
dysfunction (21, 23). 
Free radicals attack cell constituents by damaging 
protein structure, lipids and DNA sequences (Fig-
ure 2), thus increasing the risk of developing various 
lung diseases. Inhaled radicals produce adducts that 
contribute to many of the negative eff ects of tobacco 
smoke in the lung (18). Finally, the role of microorgan-
isms implicated in respiratory infections should also be 
considered. Viral and bacterial infections are associated 
with the vast majority of severe COPD exacerbations 
requiring hospitalization, and the presence of infection 
itself is related to exacerbation severity (24). Th e human 
respiratory syncytial virus (RSV) is causative agent of 
severe infections in people of all ages (25). Increased 
sputum production and cough as a consequence of 
changes in ciliary beat of the bronchial epithelium and 
in mucin production are the main clinical manifesta-
tions of COPD exacerbations; both processes may be 
aff ected by RSV, which induces the destruction of cili-
ated epithelial cells as well as an increase in mucus pro-
duction (26, 27). 
RSV-induced epithelial damage involves an oxidative 
reaction with ROS production, either by leukocytes or 
epithelial cells themselves, as mediators of the epithelial 
cell damage (28, 29). ROS intermediates are necessary 
for RSV infection and are involved in the infl amma-
tory response of host cells (30). In addition, Sethi et al.
(31) recently demonstrated that exacerbations associ-
ated with acquisition of new strains of bacteria, namely 
H. infl uenzae, S. pneumoniae, M. catarrhalis, and P. 
aeruginosa, were clearly associated with a more intense 
neutrophilic infl ammatory response in the airways, and 
with more intense systemic infl ammation, compared 
with exacerbations not associated with such strain 
acquisition. It has even been suggested that suppres-
sion of infl ammation might be more important than the 
removal of bacteria for the improvement of symptoms 
and functional abnormalities associated with COPD 
exacerbations (24). 
Second level: interaction between cellular and 
molecular mediators
It is a natural consequence that the fi rst level results in 
cellular activation, triggering a vicious oxidative cycle 
sustained by the release of infl ammatory mediators and 
proteases activation (Figure 2). Neutrophils and macro-
phages are the main cell types involved in this process 
within the lung. It is well known that neutrophils rep-
resent an important defense against bacterial and viral 
infections in the lung. On the other hand, these cells may 
promote an infl ammatory response that can contribute 
to the pathogenesis of several lung diseases, including 
COPD and severe asthma (32). 
Neutrophil activation may have several deleterious 
eff ects in the lungs. Th ese cells release proinfl ammatory 
ROS and serine proteases, including neutrophil elastase 
and proteinase-3, which may cause emphysema via 
degradation of elastin fi bers and stimulation of mucus 
secretion, and matrix metalloproteinase-8 (MMP-8) 
and MMP-9, which break down elastin and collagen. 
Furthermore, a dysregulation of MMP-3, possibly 
caused by the –1171 5A/6A polymorphism or other 
linked variants, may aff ect the progression and severity 
of COPD (33). Neutrophils themselves release factors, 
such as leukotriene B4 (LTB4) and interleukin 8 (IL-8), 
that attract other neutrophils, thereby perpetuating the 
chronic infl ammation that underlies COPD (34). 
Oxidants, either inhaled such as cigarette smoke or 
generated by leukocytes, can inactivate the α1 protease 
inhibitor, i.e. α1-antitrypsin, the inhibitor of elastase, 
by oxidation of its active site. In vitro studies indicate 
that oxidants present in cigarette smoke, as well as 
those spontaneously released by alveolar macrophages 
obtained from smokers, may induce functional inactiva-
tion of the α1 protease inhibitor, which results in the 
reduction of its inhibitory eff ect on neutrophil elastase 
(35, 36). 
Th e key point is that neutrophils, when activated, 
release proteases and neutrophil elastases from their 
granules. Hence, in cigarette smokers there is a poten-
tial for a greater protease burden. Moreover, neutro-
phils release ROS able to inactivate anti-proteases in the 
immediate peri-cellular region (5). Saetta (37) demon-
strated that also macrophages have an important role 
in airway infl ammation. In fact, these Authors found an 
increased number of macrophages and T lymphocytes 
in bronchial biopsies obtained from the central airways 
of smokers, as compared with non-smokers. Cigarette 
smoke is known to stimulate alveolar macrophages 
to release chemotactic factors for neutrophils, which 
amplifi es the oxidative vicious cycle in the lung (38). 
Consistently, a recent study demonstrated that 
lung infl ammation is generally characterized by local 
recruitment of pro-infl ammatory cells such as neutro-
phils and macrophages, which are involved in the up-
regulation of various signaling molecules, e.g. cytokines 
(TNF-α, IL-6), chemokines (IL-8) and adhesion mol-
ecules  (Figure 2). Th ese mediators, along with an 
increased ROS production, play a key role in the devel-
opment of several infl ammatory respiratory diseases, 
including COPD (39).
Third level: host defense and exogenous rescue
Th e human respiratory system has evolved biological 
mechanisms to counteract pathogenic noxae and reduce 
disease risks. With regard to oxidative stress, the close 
relationship between lung and oxygen has driven the 
respiratory system to develop a series of defense mecha-
nisms capable of reducing the potentially detrimental 
consequences of the increase in ROS and RNS. To pro-
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are endowed with effi  cient antioxidant defense systems 
such as antioxidant enzymes and non-enzymatic anti-
oxidants, including GSH, albumin, uric acid, vitamins 
C and E, and other low molecular weight organic mol-
ecules (40). Vitamin E is an interesting antioxidant sys-
tem that may also have an eff ect on lipid peroxidation. 
In particular, vitamin E has been demonstrated to dose-
dependently inhibit the receptor-mediated activation of 
neutrophils that results in the synthesis of leukotrienes 
in individuals with asthma (41). 
Among the endogenous antioxidant systems, GSH 
represents one of the most important defenses. How-
ever, GSH does not have an unlimited potential, even 
though it appears to be very active and eff ective. GSH 
is a tripeptide composed of glutamic acid, cysteine, 
and glycine. Th anks to its sulfhydryl group, it func-
tions as an antioxidant, protecting against free radicals 
and other oxidants. GSH has also been implicated in 
immune modulation and infl ammatory responses (42). 
GSH is the predominant non-protein sulfhydryl in cells, 
and plays a key role in maintaining the cellular redox 
status, defi ned as the ratio between the concentration 
of oxidizing and reducing equivalents (43). Th e de novo
synthesis of GSH from its amino-acid constituents is 
essential to face the increased GSH demand that occurs 
in response to oxidative stress. GSH synthesis involves 
two enzymatic steps catalyzed by γ-glutamylcysteine 
synthetase and glutathione synthetase (44). 
The GSH redox system
Th e GSH redox system is crucial in maintaining intra-
cellular GSH/Glutathione oxidized (GSSG) homeosta-
sis, which is critical to normal cellular physiological 
processes and represents one of the most important 
antioxidant defense systems in lung cells (44). Th is sys-
tem uses GSH as a substrate in the detoxifi cation of per-
oxides such as H2O2 and lipid peroxides, a reaction that 
involves glutathione peroxidase. Th is reaction generates 
GSSG, which is then reduced to GSH by glutathione 
reductase in a reaction requiring the hexose monophos-
phate shunt pathway involving the reduced nicotin-
amide adenine dinucleotide phosphate (NADPH). 
Maintenance of a high intracellular GSH/GSSG ratio 
(>90%) minimizes accumulation of disulphides and 
provides a reducing environment within the cell. How-
ever, when oxidants or other environmental stress alter 
this ratio, the shift in the GSH/GSSG redox buff er may 
infl uence a variety of cellular signaling processes, such 
as activation of transcription factors and cellular activa-
tion (45). Knowledge of the mechanisms of GSH regula-
tion and balance between the release and expression of 
pro- and anti-infl ammatory mediators could lead to the 
development of novel therapies based on the pharmaco-
logical manipulation of the production or gene transfer 
of this important antioxidant in lung infl ammation and 
injury (45).
It should also be noted that, besides inhibiting the 
infl ammatory response, GSH exerts other functions. 
GSH is essential for some functions of the immune sys-
tem, both innate and adaptive, which could explain the 
association between low levels of GSH and increased 
susceptibility to infections in several diseases, including 
COPD (46). Given the important role of oxidative stress 
in the pathogenesis of respiratory diseases, it has been 
proposed that antioxidant drugs such as NAC be used in 
combination with conventional therapy in the manage-
ment of these conditions. 
N-Acetylcysteine (NAC)
NAC is a precursor of GSH. Both agents act as free oxy-
gen radical scavengers. Messier et al. (47) recently dem-
onstrated that NAC provides protection against injury 
induced by cigarette smoke in alveolar type II (ATII) 
cells and lung tissue obtained from knockout mice 
lacking the nuclear factor erythroid 2-related factor-2 
(Nrf2, a redox-sensitive transcription factor that is a key 
regulator of the antioxidant defense system) both in vivo
and in vitro. Th is fi nding supports the protective role of 
NAC, which acts as a direct scavenger of free radicals 
like OH•, H2O2 and O2
−• in an Nrf2-independent man-
ner (47, 48). 
Th is new evidence is of considerable importance, 
since a reduction in Nrf2-dependent endogenous anti-
oxidants has been described in patients with COPD (8). 
Another interesting in vitro study (30) demonstrated 
that, after infl uenza virus and RSV infection, there is an 
increase in intracellular levels of H2O2 and a decrease 
in intracellular thiols. NAC restored this imbalance 
by decreasing the H2O2 concentration and restoring 
thiol levels. As a consequence, virus titers decreased 
and viral proliferation was inhibited. Finally, the same 
authors recently showed that NAC may restore epithe-
lial functions after RSV infection via inhibition of the 
expression of adhesion molecules and RSV replication, 
and by restoring antioxidant capacity, intracellular H2O2
levels and glutathione content in normal human bron-
chial epithelial cells (49). In recent years, clinical trials 
on NAC and COPD have been conducted, which allows 
more specifi c and interesting considerations. 
Mechanism of action of NAC
NAC is a thiol and mucolytic agent, a precursor of 
L- cysteine and reduced glutathione (GSH). Th e charac-
teristic of NAC of being a precursor of GSH represents 
the most important pharmacological property of this 
drug. NAC can be administered orally, via aerosol or 
intravenously. Th e drug is rapidly absorbed following 
oral administration (50), and is quickly metabolized to 
cysteine, which is a direct precursor in the synthesis of 
intracellular GSH. As such, NAC acts as an antioxidant 
by restoring the pool of intracellular reduced GSH, which 
is often depleted in conditions associated with increased 
oxidative stress and infl ammation (8, 9, 50). It has been 
shown that oral administration of NAC 600 mg/day for 
5 days signifi cantly increases GSH concentrations in the 
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compared with those who did not receive NAC (p < 0.05 
1–3 hours after the last dose of NAC) (51). 
Due to its free sulfhydryl group, which confers NAC 
with the ability to reduce disulphide bonds, the drug 
is widely used to reduce viscosity and elasticity of the 
mucus (52). As mentioned, NAC can also act as direct 
scavenger of free radicals such as OH, H2O2 and O2
−• (48). 
In a randomized, placebo-controlled trial, treatment 
with NAC signifi cantly reduced H2O2 concentration in 
the expired breath condensate of patients with stable 
COPD (53). In particular, patients treated with NAC 
600 mg/day for up to 12 months showed a progressive 
decrease from baseline in H2O2 concentration, which 
achieved statistical signifi cance after 6 months of treat-
ment (p < 0.03). After 9 and 12 months of treatment, 
the H2O2 concentration in the expired breath conden-
sate was 2.3- and 2.6-fold lower in patents treated with 
NAC as compared with placebo-treated patients (p <
0.04 and p < 0.05, respectively) (53). 
Th e antioxidant eff ect of NAC has been assessed in 
a similar study, which confi rmed NAC’s ability to sig-
nifi cantly reduce exhaled H2O2 levels in patients with 
COPD (54). In this randomized, placebo-controlled 
trial, 55 patients with stable COPD were randomized 
to receive NAC 600 mg b.i.d. (n = 32) or placebo (n =
23) for 2 months. In patients treated with NAC, exhaled 
H2O2 levels were signifi cantly reduced after 1 month of 
treatment (from 1.28 ± 0.61 μM to 0.91 ± 0.44 μM; p =
0.007 versus baseline), with a further decrease at the end 
of the second month of treatment (0.83 ± 0.41 μM; p = 
0.0001 versus baseline) (54). Conversely, no signifi cant 
changes were observed in H2O2 levels in the placebo 
group at any time point. 
Th e antioxidant properties of NAC make this drug a 
promising therapeutic agent for the modulation of cel-
lular and molecular mechanisms occurring in biologi-
cal systems (Figure 2). In particular, being NAC able to 
modulate the cellular redox status, it can interfere with 
several pathways and regulate the activity of nuclear 
factors such as nuclear transcription factor-κB (NF-
κB) (55). Specifi cally, NAC may aff ect thioredoxin and 
glutaredoxin expression, which are part of ubiquitously 
expressed thiol-reducing systems next to glutathione. 
Th ioredoxin regulates the DNA binding of NF-κB 
by reducing a cysteine of the p50 subunit, while glu-
taredoxin, by sensing the changes in the redox state of 
GSH/GSSG, may alter the signal transduction pathways 
involved in the modulation of biological responses such 
as the infl ammatory response (56). Th e diff erent mecha-
nisms of action of NAC and its possible benefi cial eff ects 
are summarized in Figure 3.
N-Acetylcysteine in the treatment of chronic bronchitis 
and COPD
Th e clinical effi  cacy of N-acetylcysteine for the treat-
ment of patients with chronic bronchitis and COPD has 
been documented in several clinical trials and metanaly-
ses (Table 1).
Figure 3. Mechanisms of action of N-acetylcysteine (NAC). NAC acts as a mucolytic, antioxidant and antinfl ammatory agent. The free sulfhydryl group confers NAC with 
the ability to reduce disulphide bonds, thus decreasing mucus viscosity and facilitating mucociliary clearance. The antioxidant activity of NAC may be both direct (the free 
sulfhydryl group may serve as a ready source of reducing equivalents) and indirect (through replenishment of intracellular GSH levels) antioxidant effects. Thus, NAC may 
break the vicious oxidative cycle by reducing oxidative stress and, subsequently, infl ammation. Overall, these effects may result in improvements in symptoms, lung function 
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once daily for 6 months. Th is multicenter, open, ran-
domized controlled trial demonstrated a statistically 
signifi cant (p < 0.05) 41% reduction in the number 
of exacerbations in the group treated with NAC, as 
compared with the control group (standard therapy). 
 Furthermore, a small but signifi cant (p < 0.001) diff er-
ence in the severity of exacerbations (as measured with 
COPD exacerbations
Th e effi  cacy of NAC in reducing the frequency of exac-
erbations was assessed in a clinical trial involving 169 
patients with moderate to severe COPD (57). Patients 
were randomized to standard therapy alone (β2-agonists, 
anticholinergics, theophylline and inhaled and/or oral 
corticosteroids) or standard therapy plus NAC 600 mg 
Table 1. Overview of the main clinical trials on the antioxidant activity and clinical effi cacy of NAC in the treatment of chronic bronchitis, COPD and COPD exacerbations
Author Condition N. Patients Study design Treatment(s) Duration Main results
Bridgeman 








34 Open, randomised 
trial; three groups of 
patients
– Not treated (n = 10)
–  NAC 600 mg/d, 
bronchoalveolar lavage 
– 1–3 hours (n = 12)
– 16–20 hours (n = 12)
After the last dose
5 days Greater GSH concentrations in the lavage fl uid 
of group 2 (lavage performed 1–3 hours after 
the last dose), as compared with controls 
(p < 0.05)







– Standard therapy (n = 84)
–  Standard therapy + NAC 
600 mg/d (n = 85)
6 months 41% reduction in the number of exacerbations 
in patients treated with NAC vs controls




COPD 44 Double-blind, placebo 
controlled, randomised 
trial
– Placebo (n = 22)
– NAC 600 mg/d (n = 22)
12 
months
Greater reduction in H2O2 concentration in 
patients treated with NAC vs controls (p < 0.04 
at 9 months and p < 0.05 at 12 months) 
Gerrits et al. 
2003 [65]
COPD 1219 Retrospective 
analysis of patients 
hospitalised for COPD, 
who had received 
N-acetylcysteine 
following discharge 
from their fi rst 
admission or had not
–  Not treated with NAC 
(n = 754)
–  Treated with NAC 200 to 
> 600 mg/d (n = 465)
Up to 1 
year
Reduction in the risk of rehospitalisation for 
COPD by about 30% in patients treated with 
NAC (RR = 0.67)
De 
Benedetto 
et al. 2005 
[54]
Stable COPD 55 Randomised placebo 
controlled trial
– Placebo (n = 23)
– NAC 600 mg/bid (n = 32)
2 months Signifi cant reduction in 
H2O2 concentration in exhaled air condensate vs 
baseline after 1 month (p < 0.007) and after 
2 months (p = 0.0001) of treatment.
Signifi cant reductions vs placebo at 1 and 
2 months.
Decramer 
et al. 2005 
[59]
Moderate COPD 523 Multicentre 
randomised, placebo-
controlled trial
– Placebo (n = 267)
– NAC 600 mg/d (n = 256)
3 years 21% reduction in exacerbations in the subgroup 
of patients treated with NAC and no inhaled 
corticosteroids vs placebo (p = 0.04)







– Placebo (n = 42)
– NAC 600 mg/d
   (n = 41)
– NAC 1.200 mg/d (n = 39)
10 days Signifi cantly higher proportion of patients 
achieving normalised CRP levels compared with 
placebo
– NAC 600 mg/d (52% of patients);
– NAC 1200 mg/d (90% of patients);
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an exacerbation severity score) was observed in favor of 
the NAC group over the control group. 
A more recent meta-analysis (58) of data from 8 
trials including a total of 2214 randomized patients 
showed that NAC signifi cantly reduced the odds of 
experiencing exacerbations over the treatment period 
by about 50% (odds ratio = 0.49, 95% CI: 0.32–0.74; p
= 0.001). Th is eff ect appeared to be attenuated by the 
use of inhaled corticosteroids, but was not aff ected by 
smoking. Overall, the results of this meta-analysis indi-
cate that NAC, by reducing the rate of exacerbations, 
may help modify the natural history of moderate-to-
severe COPD. 
Th e BRONCUS study (Bronchitis Randomized on 
NAC Cost-Utility Study) is a pivotal study on the eff ect 
of NAC in a large number of patients with COPD (59). 
In this double-blind, placebo-controlled, randomized 
study, 523 patients with COPD were followed for 3 years 
to examine the eff ects of NAC 600 mg/day versus pla-
cebo (both on top of standard therapy) on lung function 
and rate of exacerbations. To be eligible for the study, 
patients with moderate COPD had to report at least two 
exacerbations during the two years prior to the enrol-
ment. Overall, NAC failed to demonstrate an eff ect on 
the frequency of exacerbations (hazard ratio 0.99, 95% 
CI: 0.89–1.10; p = 0.85); however, a signifi cant 21% 
reduction in the rate of exacerbations was found in the 
subgroup of patients not taking inhaled corticosteroids 
(hazard ratio 0.79, 95% CI: 0.63–0.99; p = 0.04), as com-
pared with the placebo group. 
In the HIACE trial, a double blind, randomized, 
placebo-controlled trial in 120 patients with stable 
COPD treated with NAC 600 mg b.i.d. or placebo for 
1 year, the frequency of exacerbations was signifi cantly 
reduced by 44% in the NAC group as compared to the 
placebo group (0.96 versus 1.71 times/year, p = 0.019) 
(60) (Figure 6). Furthermore, at the end of the study 
more patients in the NAC group were free of exacer-
bations, as compared with those treated with placebo 
(53.8% versus 37.5%), although this result did not 
achieve statistical signifi cance (p = 0.088). Th e Authors 
concluded that the reduction in the rate of COPD 
exacerbations might be related to the antioxidant and 
antiinfl ammatory eff ects of NAC, which may lead to a 
signifi cant improvement in small airways function and 
therefore in air trapping (60). 
Th e effi  cacy of a short-term treatment with NAC 
(600 and 1200 mg/day for 10 days) on acute COPD 
exacerbations was assessed in a clinical randomized, 
double blind, placebo-controlled trial (61). Th e main 
fi nding of this study was a signifi cant reduction in 
infl ammatory markers, particularly C-reactive protein 
(PCR), associated with NAC treatment. At baseline, 
81 out of 123 patients in the three treatment arms had 
CRP levels >0.5 mg/dL. At the end of the treatment 
period, the proportion of patients whose CRP levels 
normalized was signifi cantly higher (p < 0.01) both in 
the NAC 600 mg group (52% of patients) and the NAC 
1200 mg group (90% of patients), as compared with the 
placebo group (19%) (61). Furthermore, a statistically 
signifi cant reduction in interleukin 8 (IL-8) levels was 
observed in the group treated with NAC 1200 mg/day 
(p < 0.001 versus baseline). Normalization of infl am-
matory markers was associated with clinical improve-
ments, with reductions in diffi  culty of expectoration 
(p = 0.042 and p < 0.001 in the NAC 600 mg and 1200 
mg groups, respectively) and other symptoms (e.g. 
cough frequency and intensity) (61).
A systematic review of randomized controlled trials 
(RCTs) comparing NAC with placebo was undertaken to 
analyze the eff ects of NAC treatment on COPD exacer-
bations (62). Th is analysis, which considered 11 studies 
including 2011 patients, revealed that a greater number 
of patients were free of exacerbations during treatment 
with NAC 400-600 mg/day for 3–6 months, as com-
pared to patients treated with placebo. In particular, 351 
out of 723 patients treated with NAC (48.5%) did not 
experience exacerbations during the treatment period, 
as compared with 229 out of 733 (31.2%) patients who 
received placebo (Figure 4). Th is diff erence was statisti-
cally signifi cant (p < 0.05). 
Lung hyperinfl ation
A reduction in oxidative stress and infl ammation 
by NAC in the lower respiratory tract might have a 
favorable eff ect on the phenomenon of air trapping. 
Chronic airfl ow obstruction in COPD is caused by 
a combination of small airway disease (obstructive 
bronchiolitis) and parenchymal destruction (emphy-
sema) (6). Chronic infl ammation leads to structural 
changes that result in narrowing of the small airways, 
whereas destruction of the lung parenchyma, also due 
to infl ammation, leads to loss of alveolar attachments 
to the small airways and reduces the lung elastic recoil 
(6). As a consequence, the ability of the airways to 
remain patent during expiration decreases, causing air 
trapping and lung hyperinfl ation. 
Stav et al. assessed the eff ect of NAC on lung hyper-
infl ation in a double blind, randomized, placebo-con-
trolled crossover trial in 24 patients with moderate to 
severe COPD and lung hyperinfl ation (age >40 years, 
Figure 4. Percent of patients with no COPD exacerbations during treatment with 
NAC 600 mg/day or placebo for 12–24 weeks. Meta-analysis of 11 clinical trials 
involving 2011 patients with chronic bronchitis/COPD. Difference between groups 
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FEV1 58% of predicted, mean residual volume [RV] 
to total lung capacity [TLC] ratio: 137% of predicted, 
inspiratory capacity [IC] 2.2 L) (63). Treatment with 
NAC 1200 mg/day for 6 weeks signifi cantly increased IC 
(p < 0.0033 versus placebo) and forced vital capacity 
(FVC) measured after exercise (p < 0.0029), and signifi -
cantly reduced the RV/TLC ratio after exercise (p < 0.01 
versus placebo). 
Of note, this functional improvement was associated 
with increased physical performance. Th ese fi ndings 
demonstrate that NAC may signifi cantly reduce air 
trapping caused by dynamic hyperinfl ation, even after a 
relatively short treatment period. Th e eff ects of NAC on 
airway resistance and lung hyperinfl ation have also been 
explored in the HIACE trial (60). HIACE showed that 
the antioxidant/antinfl ammatory activity of NAC may 
reduce the resistance of the lower airways, as indicated 
by a signifi cant (p = 0.037) improvement in forced expi-
ratory fl ow 25% to 75% (FEF25–75%) and forced oscillation 
technique (FOT) parameters (p < 0.05), which are used 
to specifi cally assess small airways function.
Lung function
Th e rate of decline in FEV1 was a co-primary endpoint 
of the BRONCUS study. In this study, the rate of decline 
in FEV1 was unaff ected by treatment with NAC (54 mL/
year versus 47 mL/year in the NAC and placebo group, 
respectively) (59). However, it should be noted that the 
dropout rate was signifi cantly lower in the NAC group 
than in the placebo group (27% and 37%, respectively; 
p = 0.018). Th is diff erence could explain the lack of eff ect 
on primary variables. 
Furthermore, the results of a secondary analysis of 
patients who completed the study suggest that NAC may 
have favorable eff ects on lung function in patients with 
COPD. A statistically signifi cant reduction from base-
line in functional residual capacity (FRC) was found at 
the end of the study in patients treated with NAC (mean 
diff erence: −0.374 ± 1.03; p < 0.0001), but not in those 
assigned to placebo (Figure 5). Furthermore, another 
study showed a small but signifi cant improvement in 
FEV1 in COPD patients treated with NAC 600 mg/day 
plus standard therapy for 6 months (57).
COPD symptoms
Th e aforementioned systematic review of RCTs also 
addressed the eff ect of NAC on COPD symptoms (62). 
For each trial, the percentage of patients reporting 
improvements in symptoms was higher in NAC-treated 
individuals than in those in the placebo arm. Th e diff er-
ence in favor of NAC reached statistical signifi cance in 
the largest clinical trial, consisting of 611 patients (66% of 
the total number of patients in all trials considered) (62, 
64). Th e authors of the meta-analysis concluded that of 
100 treated patients, 26 (number-needed-to-treat, 3.8) 
would report that the NAC treatment led to improve-
ment of their bronchitis-related symptoms, who would 
not have done so had they all received placebo (62). 
Hospitalizations for COPD
In the HIACE trial, a trend toward reduction in the fre-
quency of hospital admissions for COPD (0.5 times/year 
vs 0.80 times/year) and average number of hospitaliza-
tion days (1.8 days/year vs 4.2 days/year) was observed 
with NAC 600 mg b.i.d. as compared with placebo (60). 
Th is trend did not reach statistical signifi cance, likely 
due to the relatively small number of patients enrolled 
in the study. 
A retrospective analysis of 1219 patients with COPD 
aged ≥55 years and hospitalized for a COPD exacerba-
tion (65) evaluated the effi  cacy of NAC treatment fol-
lowing discharge on prevention of re-hospitalizations 
for COPD. To this aim, the population considered was 
divided into two groups, i.e. patients treated and not 
treated with NAC. All patients were studied starting 
from the fi rst discharge after a COPD exacerbation to 
their fi rst re-hospitalization, death or up to a maximum 
follow-up of one year. 
Th is study showed that NAC treatment reduced the 
risk of re-hospitalization for COPD by approximately 
30%, as illustrated by the Kaplan–Meier curve in  Figure 6 
(relative risk = 0.67; 95% Confi dence Interval [CI]: 
Figure 5. Change from baseline in functional residual capacity (FRC) in patients 
who completed the treatment period in the BRONCUS study. FRC was signifi cantly 
reduced from baseline (BL) to the end of treatment (EOT) in patients treated with 
NAC 600 mg/day (n = 120), as compared with those treated with placebo (n =
107) (59).
Figure 6. Kaplan-Meier curve showing a 30% reduction in the risk of readmission 
to hospital for COPD in patients treated (dotted line) and not treated (solid line) with 
NAC after discharge for COPD exacerbation. Risk reduction was dose-dependent. 
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0.53-0.85). Stratifi cation of patients based on average 
daily dose of NAC during the follow-up period showed 
that the risk of re-hospitalization was signifi cantly lower 
in patients treated with high daily doses of NAC, with a 
statistically signifi cant dose/response trend (p < 0.0001).
Systemic manifestation of COPD
Although primarily viewed as a respiratory dis ease, 
COPD has both pulmonary and systemic eff ects. Oxida-
tive stress is believed to play an important role in the 
systemic manifestations of COPD (66), which include 
osteoporosis and muscle wasting. Of note, besides being 
associated with reduced exercise capacity and health 
status, low fat free mass is also an independent predictor 
of mortality in COPD patients (67). Th e eff ects of NAC 
on exercise performance have been assessed in both 
healthy subjects and COPD patients. 
NAC was shown to reduce respiratory muscle fatigue 
and delay time to fatigue in healthy volunteers (68–70). A 
randomized, double-blind, placebo-controlled crossover 
study in which nine severe COPD patients performed 
localized dynamic quadriceps endurance tests at 40% of 
maximal strength after treatment with NAC (1800 mg/
day for 4 days and a last 600-mg dose on the day of the 
test) showed a signifi cant 25% improvement in endurance 
time after NAC treatment compared with placebo (71). 
In the same study, treatment with NAC prevented the 
increase in exercise-induced oxidative stress observed in 
patients treated with placebo after the test (71). 
In the study by Stav et al., treatment with NAC 1200 
mg/day for 6 weeks signifi cantly increased exercise time 
compared with placebo, with treatment diff erences of 
22 s, which was highly signifi cant (63). Conversely, in 
the HIACE trial NAC failed to improve exercise capac-
ity (60). To the best of our knowledge, no data are 
available on the eff ects of NAC on bone resorption in 
COPD patients. However, the results of a randomized, 
double-blind, placebo-controlled pilot study in early-
postmenopausal women suggest that NAC may slow 
bone resorption (72).
Tolerability
Th e effi  cacy of high-dose NAC should be balanced 
against the potential risk of side eff ects. No serious 
adverse events have been reported in clinical trials involv-
ing NAC. In the HIACE study (60), long-term treatment 
with NAC (600 mg b.i.d. for 1 year) was safe and well tol-
erated, with no signifi cant diff erences in adverse eff ects 
versus placebo (5.2% versus 8%, respectively). Chronic 
use of an even higher dose of NAC (1800 mg daily), such 
as that employed in the treatment of interstitial pulmo-
nary fi brosis in the multicenter, randomized, placebo-
controlled IFIGENIA study (73), was well tolerated. 
Conclusions
Th e antioxidant/antinfl ammatory activity of NAC, doc-
umented in both experimental and clinical pharmaco-
logical studies, may be attributed to NAC’s ability to act 
on the oxidative stress that characterizes COPD, both 
indirectly by restoring the endogenous pool of reduced 
glutathione (NAC provides cysteine for GSH biosynthe-
sis) and via a direct antioxidant eff ect (NAC contains 
a free thiol –SH group that is highly protective against 
ROS). Th e rationale for using NAC in the treatment of 
COPD is further supported by the defi nition of COPD 
provided by the recent Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines, which 
describe COPD as a disease characterized by persistent 
airfl ow limitation that is usually progressive and associ-
ated with an enhanced chronic infl ammatory response 
in the airways and the lung (6). 
Indeed, the GOLD guidelines highlight the patho-
genic role of oxidative stress resulting from inhalation 
of pro-oxidant agents and/or a reduction in endogenous 
antioxidants as an important amplifying mechanism in 
COPD (6). Similarly, the American Th oracic Society 
and the European Respiratory Society acknowledge 
that the systemic manifestations of COPD are likely to 
be, at least in part, the result of shared mechanisms 
that also contribute to the structural and functional 
changes within the lungs, including systemic infl am-
mation, altered apoptosis, and oxidative stress (74). 
NAC targets mucus hypersecretion, oxidative stress 
and infl ammation, which are all involved in the patho-
genesis of COPD. 
Th ese properties account for the favorable clinical 
outcomes achieved with short- and long-term NAC 
treatment in patients with COPD. In particular, NAC 
appears to be a valuable adjunct to standard therapy for 
preventing COPD exacerbations. Although the BRON-
CUS study failed to demonstrate a signifi cant reduction 
in exacerbation rates with NAC, several other studies 
indicate that this drug, particularly when given at high 
doses (1200 mg/day), may have benefi cial eff ects on the 
frequency and severity of COPD exacerbations. Prelimi-
nary results from the randomized, placebo-controlled 
PANTHEON study (75), which enrolled more than 1000 
patients with moderate-to-severe COPD, suggest that 
high-dose NAC (1200 mg/daily for 1 year) may reduce 
exacerbations in a signifi cant proportion of patients, 
with a better improvement in the subgroup with moder-
ate COPD (76).
Lung hyperinfl ation and exercise capacity also seem 
to be favorably aff ected by NAC treatment. Of note, 
these parameters are important predictors of health 
status. Due to the increasing interest in drugs targeting 
oxidative stress and infl ammation, and despite being an 
“old” drug, NAC has recently been the subject of several 
investigations in the fi eld of respiratory medicine. Both 
a strong rationale and the results of several clinical tri-
als that demonstrated the effi  cacy and tolerability of the 
drug support the use of NAC as an adjunct to standard 
treatment in patients with COPD. Evidence from recent 
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